# Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients

> **NCT05147896** · NA · UNKNOWN · sponsor: **University Medical Centre Ljubljana** · enrollment: 100 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Atherosclerosis

## Interventions

- **DRUG:** Semaglutide Oral Tablet

## Key facts

- **NCT ID:** NCT05147896
- **Lead sponsor:** University Medical Centre Ljubljana
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-01
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05147896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05147896, "Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05147896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*